Samsara Vision, Inc. (previously known as VisionCare Inc.) is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders.
Our lead product, the Implantable Miniature Telescope (IMT), is the first and only FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD), or Late-Stage AMD. Late-stage AMD results in a loss of central or “straight-ahead” vision, creating a blind spot that is uncorrectable by glasses, drugs, injections, or cataract surgery. It is the leading cause of blindness in older Americans.
An investigational device called the SING IMT™ (Smaller-Incision New-Generation Implantable Miniature Telescope) is being evaluated for improvements in visual acuity and safety in people living with late-stage AMD as part of the CONCERTO study, a U.S.-based Food and Drug Administration (FDA) study. Already approved in Europe, the SING IMT™ design builds upon the technology of the company’s previously FDA-approved device, the IMT, in that it can be folded and inserted through a device delivery system that allows for a smaller incision and less complicated surgery. Enrollment in CONCERTO is ongoing across the United States. (Visit www.ConcertoStudy.com for more information.)
We believe that rejuvenating eyesight, revives the spirit, allowing people to reconnect to the things in life that they love to see and do. Our approach includes working collaboratively with health care providers, researchers, payers, and advocates to ensure that people living with deteriorating vision have access to our novel technologies and support paths thereby better ensuring a future where they can see anew.